 Bio-Path Holdings Inc NASDAQ: BPTH is surging higher Tuesday after the company announced the U.S Food and Drug Administration reviewed and cleared its Investigational New Drug application for BP1002 in refractoryrelapsed acute myeloid leukemia patients. AML patients that fail frontline venetoclax-based therapy have very poor prognosis with a median overall survival of less than three months and a novel treatment modality is urgently needed for such patients, said Peter Nielsen, president and CEO of Bio-Path Holdings. 